Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention MRT-2359, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention MRT-2359, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. Their average consequence score of 5 runs below the beat's 6 for that window. MRT-6160 appears in 1 tracked Biotech story from March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MRT-6160. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings
Reported year-end financial results and updated 2027 cash runway.
Anticipated Milestone
Expected Phase 1 data readout for MRT-6160 in autoimmune diseases.
MRT-2359 Update
Released preliminary Phase 1 safety and target engagement data.
Novartis Partnership
Signed global licensing deal for MRT-6160 worth up to $2.1B.
Monte Rosa Therapeutics reported quarterly results highlighting a robust cash position following its $2.1 billion Novartis partnership. The company is accelerating its molecular glue degrader pipeline with a strategic pivot toward high-value immunology indications.
Source: themarketsdaily.com · tickerreport.com
MRT-6160 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
